Phase III
DBV Technologies aims to fill the peanut allergy treatment gap, especially for highly allergic children, with their low dose epicutaneous immunotherapy (EPIT) patch Viaskin™ Peanut.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 14, 2020.
A recent report in the New England Journal of Medicine reveals that the racial and ethnic minority groups most negatively-impacted by COVID-19 are also the least represented in these clinical studies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
Bristol Myers Squibb announced positive data from two separate Phase III clinical trials of its checkpoint inhibitor Opdivo (nivolumab).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 10, 2020.
A Genentech investigational ulcerative colitis treatment etrolizumab posted mixed results in its late-stage study program in patients who have moderate or severe active forms of the disease.
Seres Therapeutics announced positive topline data from the pivotal Phase III ECOSPOR III trial of its oral microbiome therapy SER-109 for recurrent C. difficile infection (CDI).
Genentech’s checkpoint inhibitor Tecentriq combined with chemotherapy failed to hit the mark in a Phase III metastatic triple-negative breast cancer study.
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
PRESS RELEASES